Comparing the current results to its competitors, Indaptus Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 5.65 %, recorded in the same quarter.
Indaptus Therapeutics Inc 's Comment on Competition and Industry Peers
The company faces competition from foreign and domestic pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions. Competitors may have greater capital and resources and also compete for qualified scientific and management personnel. The company’s product candidates will compete with new immunotherapies that may become available in the future. Orphan drug exclusivity can prevent approval of competing products containing the same active ingredient for the same disease or condition for seven years; however, competitors may still obtain approval for different products or for the same product for different diseases or conditions.
Publicly Traded Peers of Indaptus Therapeutics Inc
180 Life Sciences Corp Share Performance
+110.78%
Over The Past 5 Days
180 Life Sciences Corp
Profile
180 Life Sciences Corp is a biotechnology company engaged in the research and development of novel drugs that target inflammation and fibrosis to address various diseases such as fibrosis, inflammation, and pain.
Regeneron Pharmaceuticals Inc operates a business model centered on the discovery and commercialization of cutting-edge biopharmaceuticals, particularly in the fields of ophthalmology, oncology, immunology, and rare diseases. They leverage their strong research and development capabilities, including their proprietary technologies, to create innovative therapies that address unmet medical needs. Additionally, Regeneron forms strategic collaborations and partnerships to enhance their development pipeline and expand market access for their products.
Emergent Biosolutions Inc's business model focuses on developing and manufacturing specialty products for the prevention and treatment of public health threats.
Sources:
Indaptus Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Indaptus Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
